Contact the Editorial Desk

Editorial correspondence

Vyra Peptides welcomes correspondence about the research record: a citation quoted inaccurately, an effect size or confidence interval that has been corrected in an erratum, a regulatory status that has changed (for example, if retatrutide achieves approval or WADA classification), or a peer-reviewed study on tesamorelin or retatrutide that should be added to the references page.

Corrections that improve accuracy are the most useful messages this desk receives. The most actionable notes specify the page, the exact passage in question, and a supporting DOI or PubMed ID. That allows verification against the primary source quickly.

Editorial mailbox: editors@vyrapeptides.com

What this desk cannot do

Several things fall outside what this site can address — not out of indifference, but because they fall outside what a literature digest is:

• Advise on, recommend, or comment on human use of tesamorelin or retatrutide for any purpose.
• Suggest a dose, schedule, reconstitution method, or administration route for any individual.
• Diagnose a condition or assess whether a research finding applies to a particular person's situation.
• Sell, source, recommend, or help locate either compound from any supplier or vendor.
• Comment on gray-market retatrutide suppliers, vendors, or products.
• Advise athletes on anti-doping compliance, given that tesamorelin is WADA-prohibited.

Readers seeking clinical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored on a non-urgent schedule.